Blog · Global OEM & Industry Insights

2026 FDA & ASEAN Compliance Guide for Private Label Feminine Care

What brands must know about US FDA (MoCRA) and ASEAN cosmetics rules for private label feminine care in 2026 — registration vs certification, key deadlines, a compliance checklist, and the documents your OEM should provide.

For B2B buyers sourcing private label feminine care: the single most common compliance mistake we see is treating “FDA approved” as the gold standard. The US FDA does not approve cosmetics. Under the Modernization of Cosmetics Regulation Act (MoCRA), the real requirement is facility registration and product listing — and knowing that difference is how you avoid paying premium prices for marketing talk instead of regulatory substance.

This guide walks through the US FDA framework as it stands in 2026, the ASEAN market basics your products will meet from Indonesia to Vietnam, a compliance checklist you can send to any supplier, and the documentation a compliant OEM should hand you before you sign.

Who this guide is for: Brand owners, procurement managers, and importers evaluating private label feminine wash, foam, gel, spray, and wipe products for US and Southeast Asian markets.

The FDA Reality Check: Registration Is Not Certification

Under MoCRA, signed into law on December 29, 2022, cosmetic products and the facilities that manufacture them became subject to federal registration and listing requirements for the first time. Two distinct obligations matter to you as a buyer:

Neither of these is a certification. The FDA does not test, approve, or certify cosmetic products before they reach the market. So when a supplier claims an “FDA certification,” that phrase does not exist in US cosmetics regulation. What a supplier can legitimately provide is an FDA facility registration number — a verifiable, audited record that the factory is registered and current.

For feminine care products — intimate washes, foams, gels, sprays, and feminine wipes — most formulations are regulated as cosmetics in the US market, which means MoCRA registration and listing apply. Products making drug-like claims (for example, treating or preventing infection) move toward the OTC drug path and a different set of rules entirely.

MoCRA Timeline at a Glance

If your brand already sells in the US or plans to, the deadlines below are the ones your contract manufacturer is responsible for tracking — and the ones you should confirm before committing:

ObligationDeadlineWhat it means for your supply chain
MoCRA signed into lawDecember 29, 2022Facility registration and product listing become law
Existing facility registrationJuly 1, 2024Factories serving the US market registered; small businesses extended to December 29, 2024
Product listing — products already on marketJuly 1, 2024In-market products listed against a registered facility
Product listing — new productsWithin 120 days of first saleNew SKUs must be listed shortly after entering US commerce
Facility registration renewalBiennialRegistrations renew every two years — 2026 is the first renewal cycle for early registrants, so confirm your supplier’s registration is current
Product listing renewalAnnualListings renew each year; update within 180 days of any material change (e.g., reformulation or a new contract manufacturer)
Fragrance allergen labelingDecember 29, 2025Known fragrance allergens must be declared on labels

A Compliance Checklist for Brands

Send this checklist to any OEM before signing. Every item is something the supplier — or their US agent — should be able to document:

  1. FDA facility registration number — ask for it, then verify it directly against the FDA’s publicly searchable registration database.
  2. US agent details — foreign facilities must maintain a US agent responsible for FDA communications.
  3. Product listing status — your product, or a comparable product from the same line, should be listed under the facility.
  4. Ingredient and label compliance — ingredient dictionary, fragrance allergen labeling, and proper INCI names.
  5. Serious adverse event reporting — MoCRA requires reports to FDA within 15 days of a serious adverse event; confirm your partner’s process.

ASEAN Market Basics at a Glance

Across Southeast Asia, cosmetics are regulated through product notification rather than pre-market approval — but each country has its own authority, timeline, and paperwork. The differences are where most sourcing delays happen:

MarketAuthorityModelPractical note
IndonesiaBPOMProduct notification (pre-market)Notification required before marketing; Halal certification is an increasing part of the approval picture
ThailandThai FDA (TFDA)NotificationNo pre-market approval for cosmetics, but notification and labeling must be in order
MalaysiaNPRACosmetic notificationNotification is mandatory; good documentation accelerates approval
VietnamMinistry of HealthProduct announcementAnnouncement dossier must be submitted before import and sale
PhilippinesPhilippine FDACertificate of Product Notification (CPN)CPN required before products can be advertised or sold

A compliant OEM for ASEAN is one that can hand you the documents for these notifications — not promise to “take care of everything” without showing you the submission trail.

What Documentation a Compliant OEM Should Provide

Before you sign a contract, the supplier should be able to produce, in English, each of the following:

Every document above is a standard deliverable for a well-run OEM. If a factory hesitates on any of them, that is a signal — not a negotiation point.

How Zhongkang Bainian Handles FDA & ASEAN Compliance

Zhongkang Bainian factory and R&D — regulatory-compliant private label feminine care OEM

Zhongkang Bainian is a private label OEM/ODM manufacturer for feminine care in Quanzhou, China, with a 20,000 m² self-owned industrial park and a 100K-class (ISO 8) clean workshop. Compliance is built into how we work, not bolted on per order:

Our compliance team is the same team that builds your product — so the paperwork and the formulation never drift apart.

Summary

The regulatory picture for private label feminine care in 2026 rewards one thing above all: documentation you can verify. In the US that means an FDA facility registration number and product listings you can confirm yourself, not a supplier’s claim of approval. In ASEAN it means notification records for each target market, submitted under the right authority, in the right language.

Use the checklist in this guide as your conversation starter with any OEM. If a supplier can walk you through facility registration, product listing, test reports, and ASEAN notification documents without hesitation — and show you the records — you have found a partner who treats compliance as a capability, not a sales pitch.

If you are evaluating manufacturing partners for the US or Southeast Asia, feel free to contact us. We can walk you through the documentation for your target markets, compare what different suppliers actually hold, and support a clean, compliant launch of your private label concept.

Partner With a Manufacturer That Checks Every Box

Zhongkang Bainian is an R&D-led OEM/ODM manufacturer for private label feminine care and wellness products. US FDA facility registration, ASEAN documentation support, disinfectant licensing, and third-party efficacy testing are things we do in-house for 1,000+ brand partners across global markets.

*This guide is for informational purposes only. Regulations and deadlines reflect publicly available information at the time of writing and may change. Always verify current requirements directly with the relevant regulatory authority and your own counsel before making sourcing decisions.*